AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Stake Raised by State Street Corp

State Street Corp boosted its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 75.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,522,059 shares of the specialty pharmaceutical company’s stock after buying an additional 1,082,366 shares during the period. State Street Corp owned approximately 7.20% of AMAG Pharmaceuticals worth $56,876,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock valued at $112,647,000 after buying an additional 4,988,054 shares in the last quarter. Vanguard Group Inc. raised its position in shares of AMAG Pharmaceuticals by 6.1% in the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock valued at $69,576,000 after buying an additional 176,832 shares during the last quarter. LSV Asset Management raised its position in shares of AMAG Pharmaceuticals by 34.0% in the first quarter. LSV Asset Management now owns 1,685,098 shares of the specialty pharmaceutical company’s stock valued at $37,998,000 after buying an additional 427,238 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of AMAG Pharmaceuticals by 777.8% in the first quarter. Acadian Asset Management LLC now owns 1,226,690 shares of the specialty pharmaceutical company’s stock valued at $27,659,000 after buying an additional 1,086,937 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of AMAG Pharmaceuticals by 152.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock valued at $23,129,000 after buying an additional 619,370 shares during the last quarter.

Shares of AMAG Pharmaceuticals, Inc. (AMAG) opened at 17.50 on Thursday. The company’s market capitalization is $613.29 million. The stock has a 50 day moving average of $19.12 and a 200-day moving average of $20.89. AMAG Pharmaceuticals, Inc. has a 52 week low of $16.00 and a 52 week high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.18. The company had revenue of $158.39 million for the quarter, compared to analyst estimates of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm’s revenue was up 24.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.45 earnings per share. On average, analysts anticipate that AMAG Pharmaceuticals, Inc. will post ($0.41) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “[[title]]” was originally published by [[site]] and is owned by of [[site]]. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at [[permalink]].

Several brokerages recently issued reports on AMAG. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Cantor Fitzgerald reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. Deutsche Bank AG set a $24.00 price target on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, July 7th. Finally, Citigroup Inc. reduced their price objective on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a research note on Friday, July 7th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $28.09.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the transaction, the senior vice president now owns 28,336 shares of the company’s stock, valued at $566,720. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 3.80% of the company’s stock.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.